A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Inclusion Criteria: 1. Females treated for the first time, 18-75 years old; 2. ECOG score 0-1; 3. Has pathological diagnosis that meets the criteria: confirmed HER2 positive; 4. Results of laboratory tests meet the enrollment requirements; 5. Pregnancy test result must be negative and must agree to contraception; 6. Has signed the informed consent form. Exclusion Criteria: 1. Confirmed HER2 negative; 2. Has tumor-related medical history or treatment history; 3. Has severe combined disease/medical history and treatment history; 4. Has received treatment with systemic immunostimulants or immunosuppressants; 5. Be allergic to the test drug; 6. Participate in other clinical trials simultaneously; 7. Has received vaccine within 30 days before the first dose; 8. Has received allograft bone marrow transplantation; 9. Has given birth within one year or is breastfeeding; 10. Has history of psychological drug abuse, alcoholism or drug use.